*Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH †Department of Pathology, University of California Los Angeles, Los Angeles, CA ‡Department of Anatomic Pathology ¶Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN §Department of Pathology, Brigham and Women's Hospital, Boston, MA ∥British Columbia Cancer Agency, Vancouver, BC, Canada.
Am J Surg Pathol. 2014 Jun;38(6):768-75. doi: 10.1097/PAS.0000000000000188.
The diagnosis of peripheral T-cell and NK-cell lymphomas (PTNKCL) is difficult with few standards for required ancillary studies. We evaluated a series of PTNKCLs using a tiered approach to immunohistochemistry and molecular genetic characterization to document diagnostic accuracy and clinical relevance. Seven hematopathologists reviewed 374 cases that included PTNKCL and non-PTNKCL cases to mimic diagnostic practice. Cases received tier 0, 1, and 2 diagnoses by 3 independent pathologists, on the basis of hematoxylin and eosin stains and progressive immunohistochemistry panels. A tier 2b diagnosis was rendered when gene rearrangement data were available, and a final consensus diagnosis was rendered after discussion of each case. Across all 374 cases, consensus agreement was 92.5%. For PTNKCLs, World Health Organization subclassification was possible in 16.5%, 37.1%, 82.8%, and 85.9% of individual reviewer diagnoses at tier 0, 1, 2, and 2b, respectively. Gene rearrangement contributed to a change in diagnosis in 51 of 647 (8%) individual reviews. Following this algorithm may provide prognostic information on the basis of individual marker expression in common PTNKCL types (CD4 in peripheral T-cell lymphoma, not otherwise specified and PD-1 in angioimmunoblastic T-cell lymphoma). This evidence-based approach to the diagnosis of PTNKCL informs practicing pathologists, clinical trial designers, and policy-makers regarding required ancillary studies.
外周 T 细胞和 NK 细胞淋巴瘤(PTNKCL)的诊断具有一定难度,因为很少有辅助研究的标准。我们采用分层免疫组化和分子遗传学特征分析的方法,评估了一系列 PNTKCL,以记录诊断准确性和临床相关性。7 名血液病理学家对包括 PNTKCL 和非 PNTKCL 病例的 374 例病例进行了评估,以模拟诊断实践。3 位独立病理学家根据苏木精和伊红染色和逐步免疫组化面板,对这些病例进行了 0 级、1 级和 2 级诊断。当存在基因重排数据时,可进行 2b 级诊断,并且在讨论每个病例后,可做出最终共识诊断。在所有 374 例病例中,共识一致性为 92.5%。对于 PNTKCL,在 0 级、1 级、2 级和 2b 级的单独诊断中,分别有 16.5%、37.1%、82.8%和 85.9%的病例可进行世界卫生组织分类。在 647 例单独评估中,基因重排导致 51 例(8%)的诊断发生改变。遵循此算法可以根据常见 PNTKCL 类型(非特指外周 T 细胞淋巴瘤中的 CD4 和血管免疫母细胞性 T 细胞淋巴瘤中的 PD-1)中单个标志物的表达提供预后信息。这种基于证据的 PNTKCL 诊断方法为临床病理学家、临床试验设计者和决策者提供了关于辅助研究的信息。